BDX Strangle Strategy
BDX (Becton, Dickinson and Company), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NYSE.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
BDX (Becton, Dickinson and Company) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $52.24B, a trailing P/E of 35.56, a beta of 0.29 versus the broader market, a 52-week range of 127.58648-187.35, average daily share volume of 2.8M, a public-listing history dating back to 1973, approximately 70K full-time employees. These structural characteristics shape how BDX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.29 indicates BDX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 35.56 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple. BDX pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on BDX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current BDX snapshot
As of May 15, 2026, spot at $143.49, ATM IV 27.70%, IV rank 30.12%, expected move 7.94%. The strangle on BDX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on BDX specifically: BDX IV at 27.70% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 7.94% (roughly $11.40 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BDX expiries trade a higher absolute premium for lower per-day decay. Position sizing on BDX should anchor to the underlying notional of $143.49 per share and to the trader's directional view on BDX stock.
BDX strangle setup
The BDX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BDX near $143.49, the first option leg uses a $150.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BDX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BDX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $150.00 | $2.08 |
| Buy 1 | Put | $135.00 | $1.93 |
BDX strangle risk and reward
- Net Premium / Debit
- -$400.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$400.00
- Breakeven(s)
- $131.00, $154.00
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
BDX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on BDX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$13,099.00 |
| $31.74 | -77.9% | +$9,926.47 |
| $63.46 | -55.8% | +$6,753.93 |
| $95.19 | -33.7% | +$3,581.40 |
| $126.91 | -11.6% | +$408.87 |
| $158.64 | +10.6% | +$463.66 |
| $190.36 | +32.7% | +$3,636.20 |
| $222.09 | +54.8% | +$6,808.73 |
| $253.81 | +76.9% | +$9,981.26 |
| $285.54 | +99.0% | +$13,153.79 |
When traders use strangle on BDX
Strangles on BDX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BDX chain.
BDX thesis for this strangle
The market-implied 1-standard-deviation range for BDX extends from approximately $132.09 on the downside to $154.89 on the upside. A BDX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current BDX IV rank near 30.12% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on BDX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, BDX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BDX-specific events.
BDX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BDX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BDX alongside the broader basket even when BDX-specific fundamentals are unchanged. Always rebuild the position from current BDX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on BDX?
- A strangle on BDX is the strangle strategy applied to BDX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With BDX stock trading near $143.49, the strikes shown on this page are snapped to the nearest listed BDX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BDX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BDX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 27.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$400.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BDX strangle?
- The breakeven for the BDX strangle priced on this page is roughly $131.00 and $154.00 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BDX market-implied 1-standard-deviation expected move is approximately 7.94%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on BDX?
- Strangles on BDX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BDX chain.
- How does current BDX implied volatility affect this strangle?
- BDX ATM IV is at 27.70% with IV rank near 30.12%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.